Editorial Board Member

Amedeo Lonardo
Operating Unit of Metabolic Syndrome, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy.
HomePage
Research Interests
metabolic associated fatty liver disease, non-alcoholic fatty liver disease, endocrine disorders, sex differences in non-alcoholic fatty liver disease, metabolic syndrome, liver, hypobetalipoproteinemia, dysmetabolism in hepatitis C virus infection, diabetes in cirrhosis
Contributions:

Editorial: Metabolism and Target Organ Damage

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies

The Fatty liver Index (FLI) 15 years later: a reappraisal

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Commentary: Of women, liver, and heart

Concise review: Breastfeeding, lactation, and NAFLD. An updated view of cross-generational disease transmission and prevention

Is liver fibrosis a risk factor for gynecological cancers?

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Could controversies in the arena of fatty liver disease be a potential gate for the democratization of science?

Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge

Copper and liver fibrosis in MASLD: the two-edged sword of copper deficiency and toxicity

Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease

PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology

Special Issue:

Organ Dysfunction in Metabolic-Associated Fatty Liver Disease: Effect of Cofactors

Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/